Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

BioSyent Schedules Q3 and YTD 2023 Earnings Release for November 16, 2023


MISSISSAUGA, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2023 on Thursday, November 16, 2023 before market hours. A presentation on the Company's third quarter and year-to-date 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 11,824,618 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.



These press releases may also interest you

at 06:05
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced longer-term data updates from its lentiviral (LV)...

at 06:00
Medical Polymer Market worth $60.5 billion by 2029 - Exclusive Report by MarketsandMarketstm
The report "Medical Polymer Market by type (Medical plastics, Medical elastomers), Application (Medical Disposables, Medical Instruments and Devices, Prosthetics, Diagnostics Instruments and Tools), Manufacturing Technology, and Region - Global...

at 06:00
Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration
Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion Broad GCase elevation achieved in NHPs, while significantly...

at 06:00
Celebrate Women During Women's Health Week with Women's Excellence
As we head into Women's Health Week, Women's Excellence is proud to reaffirm its dedication to the well-being and empowerment of women across Metro Detroit. From May 12th to May 18th, our practice joins the nationwide effort to highlight the...

at 06:00
Affinia Therapeutics Presents Preclinical Data for Genetic Cardiomyopathy and Sporadic ALS Programs with Novel Cardiotropic and BBB-Penetrant AAV Capsids at the American Society of Gene & Cell Therapy 2024 Annual Meeting
...

at 05:45
Investors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact The Gross Law Firm Before June 11, 2024 to Discuss Your Rights - QDEL
The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation . Shareholders who...

More news about Health...


News published on and distributed by: